| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2014-01-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2022-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12e8efdc7fe59acfa682d6ede3d25df3 |
| publicationDate |
2022-06-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2897814-C |
| titleOfInvention |
Deuterated momelotinib |
| abstract |
The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein one or more of the variables shown in Formula I are deuterium. The deuterium modification of Formula I may positively impact the ADME properties of the compound, creating the potential for improved drug efficacy, safety, and/or tolerability. The compound of Foimula I potentially can be used in the treatment of disorders that may be treated by an inhibitor of Janus kinase 1 (JAKI) and Janus kinase 2 (JAK2). |
| priorityDate |
2013-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |